Health officials have issued an urgent warning regarding Candida auris (C.auris), a deadly drug-resistant fungal infection rapidly spreading through hospitals in Europe. Previously described by the World Health Organization (WHO) as 'a serious threat to humanity' and identified as one of 19 lethal fungi in its critical priority group—alongside Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans—C.auris is becoming increasingly resistant to the limited number of existing antifungal drugs.

A recent report from the European Centre for Disease Prevention and Control (ECDC) revealed that over 4,000 people were infected with C.auris in Europe between 2013 and 2023. In 2023 alone, 1,346 cases were reported, marking a significant 67 percent increase from the previous year. The ECDC stated that "Case numbers are rising, outbreaks are growing in scale, and several countries report ongoing local transmission." Alarmingly, nearly 60 percent of those who contract this severe infection die within 90 days.

C.auris, which can survive on hospital surfaces and human skin for extended periods, typically spreads in healthcare facilities and disproportionately affects critically ill patients. It can cause serious infections in various parts of the body, including the blood, brain, spinal cord, bones, ears, respiratory system, and urinary tract. Sampling in British hospitals has detected traces of the fungus on medical equipment, radiators, windowsills, and sinks, highlighting these areas as potential infection hotspots. Its resistance to most treatments makes it exceptionally difficult to eradicate.

Since its first identification in Japan in 2009, C.auris has spread across more than 40 countries over six continents. In Europe, at least 18 countries have reported cases in the last decade, with Spain, Greece, Italy, Romania, and Germany accounting for the highest numbers. Recent outbreaks have also occurred in hospitals in Cyprus and France. A notable incident in 2016 saw the Royal Brompton Hospital in London forced to close its intensive care unit after three patients died and a further 50 were infected following a C.auris outbreak.

Experts attribute the surge in cases primarily to inadequate surveillance systems, which allow the fungus to establish itself undetected in hospitals, as well as difficulties in promptly diagnosing infections. Rising temperatures are also considered a factor, as they provide optimum conditions for fungi to thrive. Dr. Diamantis Plachouras, head of antimicrobial resistance and healthcare-associated infections at the ECDC, emphasized, "C.auris has spread within only a few years—from isolated cases to becoming widespread in some countries. But this is not inevitable. Early detection and rapid, coordinated infection control can still prevent further transmission."

The broader issue of antimicrobial resistance, particularly with "superbugs" that resist existing drugs, represents an urgent global health crisis. Fungal infections pose a particular challenge because developing new antifungal medicines is difficult, as fungal cells are remarkably similar to human cells. Consequently, only four new antifungal drugs have been approved by regulatory authorities in the last ten years. Projections suggest that by 2050, 10 million people will die annually from resistant infections. In the UK, all C.auris cases must now be reported to health authorities to curb further outbreaks.